Metaldehyde Toxicosis

Metaldehyde toxicosis is a potentially fatal poisoning caused by the ingestion of metaldehyde, a cyclic tetramer of acetaldehyde, commonly used as a molluscicide in slug and snail baits. The compound is highly toxic to dogs and cats, with a narrow margin of safety. Clinical signs typically develop within 1-3 hours of ingestion and are characterized by severe neurological dysfunction, including tremors, ataxia, seizures, hyperthermia, and metabolic acidosis. The severity of signs is dose-dependent, and without prompt and aggressive treatment, the condition can progress to status epilepticus, respiratory failure, and death. Metaldehyde is rapidly absorbed from the gastrointestinal tract, and its toxic effects are primarily mediated through its metabolite, acetaldehyde, which disrupts neurotransmitter balance, particularly serotonin and gamma-aminobutyric acid (GABA), leading to central nervous system excitation. The condition is a medical emergency requiring immediate decontamination, symptomatic control of seizures, and supportive care.

Metaldehyde toxicosis is caused by the ingestion of metaldehyde-containing products, most commonly slug and snail baits. These baits are formulated as pellets, granules, powders, or liquids and often contain metaldehyde at concentrations ranging from 1.5% to 5%. The toxic dose for dogs is approximately 100-200 mg/kg, but clinical signs can occur at lower doses, especially in small breeds or cats. Metaldehyde is rapidly absorbed from the gastrointestinal tract, with peak plasma concentrations occurring within 1-3 hours. The compound is metabolized in the liver to acetaldehyde, which is believed to be the primary toxic metabolite. Acetaldehyde interferes with the metabolism of gamma-aminobutyric acid (GABA), leading to decreased GABAergic inhibition and increased neuronal excitability. Additionally, metaldehyde may inhibit monoamine oxidase, resulting in altered serotonin and catecholamine levels. The exact molecular mechanisms are not fully understood, but the net effect is severe central nervous system stimulation. Other sources of metaldehyde include fuel tablets for camping stoves and certain industrial products, though these are less common in veterinary practice.

Metaldehyde toxicosis is most commonly reported in dogs, particularly those with a tendency to scavenge or ingest non-food items. Puppies and young adult dogs are at higher risk due to their exploratory behavior. Cats are less commonly affected, but can be poisoned if they ingest bait directly or groom contaminated fur. The condition is more prevalent in regions with high slug and snail populations, such as temperate climates with moist conditions, and during spring and summer months when gardeners use molluscicides. There is no breed or sex predisposition, although small breeds may exhibit more severe clinical signs at lower doses due to their lower body weight. The incidence of metaldehyde toxicosis varies by geographic region, but it is a significant cause of poisoning in small animal practice, with some studies reporting it as one of the most common toxicoses in dogs. In the United Kingdom, metaldehyde is a leading cause of canine poisoning, and similar trends are observed in other parts of Europe and North America.

The pathophysiology of metaldehyde toxicosis is complex and involves multiple mechanisms. After ingestion, metaldehyde is rapidly absorbed from the gastrointestinal tract and distributed throughout the body, with high concentrations in the liver, brain, and kidneys. The liver metabolizes metaldehyde to acetaldehyde, which is further oxidized to acetic acid. Acetaldehyde is highly reactive and can bind to cellular proteins and DNA, leading to cellular damage. The primary neurotoxic effect is believed to be due to the inhibition of GABA receptors and the enhancement of glutamatergic transmission, resulting in excessive neuronal excitation. Metaldehyde also inhibits monoamine oxidase, leading to increased levels of serotonin and catecholamines, which contribute to the hyperexcitability and tremors. Additionally, acetaldehyde can cause mitochondrial dysfunction and oxidative stress, leading to neuronal injury. The severe muscle tremors and seizures increase metabolic demand, leading to hyperthermia, lactic acidosis, and respiratory alkalosis followed by metabolic acidosis. Hyperthermia can exacerbate neuronal damage and lead to multi-organ failure. The toxic effects on the liver and kidneys may result in hepatic and renal dysfunction, although these are less common than neurological signs. The overall pathophysiological cascade results in a life-threatening neurological emergency.

Several factors predispose animals to metaldehyde toxicosis. Intrinsic factors include age, with puppies and kittens being more curious and likely to ingest toxic substances. Small breed dogs may be at higher risk due to their lower body weight, making them more susceptible to the toxic effects of a given dose. Additionally, animals with a history of pica or indiscriminate eating are at increased risk. Extrinsic factors include the availability of metaldehyde-containing products in the environment, such as gardens, garages, and storage areas. Improper storage of baits, such as leaving them in accessible locations, increases the risk of accidental ingestion. Seasonal factors, particularly spring and summer, when slug and snail activity is high, lead to increased use of molluscicides and thus higher exposure risk. Concurrent medical conditions, such as hepatic or renal disease, may impair metabolism and excretion of metaldehyde, increasing the severity of toxicity. Additionally, animals that are already debilitated or stressed may have reduced tolerance to the toxic effects.

Clinical signs of metaldehyde toxicosis typically appear within 1-3 hours of ingestion and progress rapidly. The severity of signs is dose-dependent. Early signs include anxiety, restlessness, hypersalivation, vomiting, and ataxia. As toxicity progresses, fine muscle tremors become evident, which can progress to severe generalized tremors and seizures. Hyperthermia is common due to excessive muscle activity, with body temperatures often exceeding 40°C (104°F). Tachycardia, tachypnea, and hyperesthesia are also observed. In severe cases, seizures may become continuous (status epilepticus), leading to respiratory compromise, cyanosis, and death. Other signs may include diarrhea, abdominal pain, and dehydration. Neurological signs can persist for 24-72 hours, and some animals may develop permanent neurological deficits. In cats, clinical signs are similar but may include more pronounced hypersalivation and vocalization. The clinical course can be divided into peracute (within 1-2 hours), acute (2-24 hours), and subacute (24-72 hours) stages. Peracute signs are primarily gastrointestinal and mild neurological; acute signs include severe tremors and seizures; subacute signs may involve residual ataxia and depression.

Differential diagnoses for metaldehyde toxicosis include other causes of acute onset tremors and seizures in dogs and cats. These include: 1) Strychnine toxicosis: causes severe extensor rigidity and seizures, but tremors are less prominent; onset is rapid, and there is no hyperthermia unless seizures are prolonged. 2) Organophosphate or carbamate toxicosis: causes muscarinic signs (salivation, lacrimation, urination, defecation, vomiting) and nicotinic signs (muscle fasciculations, weakness), but seizures are less common; response to atropine and pralidoxime is diagnostic. 3) Ethylene glycol toxicosis: causes acute renal failure, neurological signs (ataxia, depression), and metabolic acidosis; calcium oxalate crystals in urine and ultrasonographic renal changes are diagnostic. 4) Hypoglycemia: causes tremors, seizures, and weakness; blood glucose measurement is diagnostic. 5) Hepatic encephalopathy: causes neurological signs, but typically more chronic; elevated liver enzymes and bile acids are diagnostic. 6) Idiopathic epilepsy: causes recurrent seizures, but no tremors or hyperthermia unless seizures are prolonged; history and lack of toxin exposure are key. 7) Toxicosis from other pesticides (e.g., pyrethrins, bromethalin): pyrethrin toxicosis causes tremors and hypersalivation, but seizures are less common; bromethalin causes cerebral edema and neurological signs, but onset is delayed. 8) Infectious encephalitis (e.g., canine distemper, rabies): causes neurological signs, but typically with other systemic signs and a history of exposure. Definitive diagnosis of metaldehyde toxicosis is based on history of exposure, clinical signs, and response to treatment; laboratory confirmation can be performed on gastric contents or serum.

The diagnostic approach to suspected metaldehyde toxicosis should be systematic and rapid. 1) Obtain a thorough history, including recent exposure to slug/snail baits or other metaldehyde-containing products. 2) Perform a complete physical examination, with emphasis on neurological status, body temperature, and cardiovascular parameters. 3) Initiate emergency stabilization if the animal is seizing or hyperthermic: administer anticonvulsants (e.g., diazepam, phenobarbital), cool the animal with IV fluids and cold packs, and provide oxygen if needed. 4) Collect blood samples for baseline laboratory evaluation: CBC, serum biochemistry, blood gas analysis, and lactate measurement. 5) If the animal is stable, consider gastric decontamination: induce emesis only if the animal is conscious and not seizing, and if ingestion occurred within 1-2 hours; administer activated charcoal with a cathartic. 6) Submit gastric contents or serum for metaldehyde analysis if available, but treatment should not be delayed for confirmation. 7) Monitor the animal closely for progression of neurological signs and complications such as hyperthermia, acidosis, and respiratory failure. 8) Rule out other causes of tremors and seizures through appropriate diagnostic testing (e.g., blood glucose, electrolyte panel, liver function tests, toxin screens). 9) Provide supportive care and symptomatic treatment as needed. The diagnosis is often presumptive based on history and clinical signs, and response to treatment supports the diagnosis.

Laboratory findings in metaldehyde toxicosis are non-specific but can support the diagnosis and guide treatment. Complete blood count (CBC) may show stress leukogram (leukocytosis, neutrophilia, lymphopenia) due to catecholamine release. Serum biochemistry may reveal elevated muscle enzymes (creatine kinase, aspartate aminotransferase) due to muscle tremors and seizures. Liver enzymes (alanine aminotransferase, alkaline phosphatase) may be elevated due to hepatic hypoxia or direct toxic effects. Blood gas analysis often reveals metabolic acidosis (decreased pH, decreased bicarbonate) due to lactic acidosis from severe muscle activity and tissue hypoxia. Respiratory alkalosis may be present initially due to hyperventilation. Serum lactate is typically elevated. Electrolyte abnormalities may include hyperkalemia or hypokalemia, depending on the duration and severity of seizures. Blood glucose may be normal or elevated due to stress, but hypoglycemia should be ruled out. Urinalysis may show myoglobinuria due to rhabdomyolysis, which can lead to acute kidney injury. Specific biomarkers such as troponin I may be elevated if myocardial damage occurs. Metaldehyde can be detected in serum, urine, or gastric contents using gas chromatography-mass spectrometry, but this is not routinely available. In practice, the diagnosis is based on history and clinical signs, and laboratory findings are used to assess the severity of metabolic derangements and guide supportive care.

Imaging studies are not typically necessary for the diagnosis of metaldehyde toxicosis, but they may be performed to rule out other causes of neurological signs or to assess complications. Thoracic radiography may be indicated if aspiration pneumonia is suspected due to vomiting or seizures. Abdominal radiography may be performed to identify radiopaque material in the gastrointestinal tract, but metaldehyde baits are not consistently radiopaque. Ultrasonography may be useful to assess liver and kidney morphology and to rule out other abdominal pathology. Computed tomography (CT) or magnetic resonance imaging (MRI) of the brain may be considered if there is suspicion of intracranial disease, but these are not routinely indicated and may require anesthesia, which is risky in a seizing animal. In general, imaging is of limited diagnostic value in metaldehyde toxicosis and should be reserved for cases with atypical presentation or suspected concurrent disease.

Cytological and histopathological findings in metaldehyde toxicosis are not commonly used for diagnosis, as the condition is typically diagnosed based on history and clinical signs. However, if necropsy is performed, histopathological changes may include neuronal degeneration and necrosis in the brain, particularly in the cerebral cortex and cerebellum. Hepatic changes may include centrilobular necrosis and fatty change. Renal changes may include tubular necrosis. Muscle tissue may show rhabdomyolysis. These findings are non-specific and can be seen in other toxicities or hypoxic conditions. Cytological examination of gastric contents may reveal the presence of metaldehyde crystals, but this is not a routine diagnostic test. In clinical practice, histopathology is rarely performed antemortem, and the diagnosis is based on clinical presentation and response to treatment.

Treatment of metaldehyde toxicosis is primarily symptomatic and supportive, with the goals of controlling seizures, managing hyperthermia, correcting acid-base and electrolyte imbalances, and providing supportive care. The following steps are recommended: 1) Emergency stabilization: If the animal is seizing, administer diazepam (0.5-1 mg/kg IV, can be repeated up to 3 times) or midazolam (0.2-0.3 mg/kg IV). If seizures are refractory, administer phenobarbital (2-4 mg/kg IV, may be repeated up to a total of 20 mg/kg) or propofol (1-4 mg/kg IV, then CRI at 0.1-0.4 mg/kg/min). 2) Decontamination: If ingestion occurred within 1-2 hours and the animal is not seizing, induce emesis with apomorphine (0.03 mg/kg IV or 0.04 mg/kg IM) or hydrogen peroxide (1-2 mL/kg PO, up to 50 mL). Administer activated charcoal (1-2 g/kg PO) with a cathartic (e.g., sorbitol) to reduce absorption. Do not induce emesis if the animal is seizing or has a decreased gag reflex. 3) Fluid therapy: Administer intravenous crystalloids (e.g., lactated Ringer's solution or 0.9% NaCl) at a rate to correct dehydration and maintain perfusion (e.g., 60-100 mL/kg/day for maintenance, plus deficits). Add potassium chloride as needed based on serum potassium levels. 4) Hyperthermia management: Cool the animal with cool water, fans, and cold packs applied to the groin and axillae. Discontinue cooling when temperature reaches 39.5°C (103°F) to avoid hypothermia. 5) Acid-base and electrolyte correction: Metabolic acidosis usually resolves with fluid therapy and seizure control; if severe (pH < 7.1), consider sodium bicarbonate (0.5-1 mEq/kg IV slowly). 6) Muscle relaxants: Methocarbamol (55-220 mg/kg IV, slow, up to a maximum of 330 mg/kg/day) can be used to control tremors if seizures are not present. 7) Additional anticonvulsants: If seizures are refractory, consider levetiracetam (20-60 mg/kg IV q8h) or a continuous rate infusion of propofol. 8) Supportive care: Provide oxygen if hypoxemia is present, monitor cardiac rhythm, and provide nutritional support if the animal is unable to eat for more than 24 hours. 9) Monitor for complications: Aspiration pneumonia, acute kidney injury, and hepatic dysfunction should be monitored and treated accordingly. 10) In severe cases, mechanical ventilation may be necessary if respiratory failure occurs.

The prognosis for metaldehyde toxicosis is generally good with prompt and aggressive treatment, but it depends on the dose ingested, the time to treatment, and the severity of clinical signs. Animals that present with mild tremors and are treated early have an excellent prognosis. Animals that present with severe seizures, hyperthermia, or respiratory compromise have a guarded prognosis. Mortality rates range from 3% to 10% in treated cases, but can be higher if treatment is delayed or if complications such as aspiration pneumonia or acute kidney injury develop. Negative prognostic indicators include prolonged seizures, hyperthermia >41°C (106°F), severe metabolic acidosis, and the development of disseminated intravascular coagulation. Most animals that survive the acute phase (24-72 hours) recover fully, although some may have residual neurological deficits such as ataxia or behavioral changes. Long-term prognosis is excellent if the animal survives the initial toxic episode.

Follow-up care for animals recovering from metaldehyde toxicosis is important to monitor for complications and ensure complete recovery. The animal should be hospitalized for at least 24-48 hours after clinical signs resolve, as relapses can occur. During hospitalization, monitor vital signs, neurological status, and laboratory parameters (blood gas, electrolytes, renal and liver function) every 12-24 hours. After discharge, the owner should be advised to monitor for any recurrence of neurological signs, which may occur if the animal ingested a large amount or if there is delayed absorption. A recheck examination is recommended 3-7 days after discharge to assess recovery and to evaluate for any organ dysfunction. If the animal had elevated liver enzymes or renal parameters, repeat blood work in 2-4 weeks to ensure normalization. If the animal developed aspiration pneumonia, thoracic radiographs should be repeated in 1-2 weeks. Long-term management includes preventing further exposure to metaldehyde-containing products, such as using pet-safe alternatives or storing baits in inaccessible locations. Owners should be educated on the importance of immediate veterinary care if ingestion is suspected.

Pearls: 1) Metaldehyde toxicosis should be suspected in any dog or cat presenting with acute onset tremors or seizures, especially if there is a history of access to slug/snail baits. 2) Hyperthermia is a common and dangerous complication; aggressive cooling is essential. 3) Seizures may be refractory to standard anticonvulsants; a multimodal approach with diazepam, phenobarbital, and propofol may be necessary. 4) Methocarbamol is a valuable adjunct for controlling tremors without causing excessive sedation. 5) Early decontamination with emesis and activated charcoal can significantly reduce the severity of clinical signs. 6) Metabolic acidosis is usually self-correcting with seizure control and fluid therapy; avoid overuse of sodium bicarbonate. 7) Prognosis is excellent with prompt treatment, even in severe cases. Pitfalls: 1) Do not induce emesis in a seizing or obtunded animal due to the risk of aspiration. 2) Do not delay treatment for laboratory confirmation; treat based on history and clinical signs. 3) Avoid using cold water baths that can cause shivering and increase metabolic rate; use cool water and fans. 4) Do not use phenothiazine tranquilizers (e.g., acepromazine) as they may lower the seizure threshold. 5) Do not forget to monitor for aspiration pneumonia, especially if vomiting occurred. 6) Do not discharge the animal too early; clinical signs can recur within 24-48 hours. 7) Do not overlook the possibility of concurrent toxicities, such as metaldehyde and other pesticides.

The following drug protocols are based on Plumb's Veterinary Drug Handbook and current veterinary toxicology guidelines. 1) Diazepam: 0.5-1 mg/kg IV, can be repeated up to 3 times; if effective, can be given as a CRI at 0.1-0.5 mg/kg/hour. 2) Midazolam: 0.2-0.3 mg/kg IV, can be repeated; CRI at 0.1-0.3 mg/kg/hour. 3) Phenobarbital: 2-4 mg/kg IV, can be repeated up to a total of 20 mg/kg; maintenance at 2-3 mg/kg PO q12h if needed. 4) Propofol: 1-4 mg/kg IV for induction, then CRI at 0.1-0.4 mg/kg/min for refractory seizures. 5) Methocarbamol: 55-220 mg/kg IV, slow, up to a maximum of 330 mg/kg/day; can be given PO at 44-66 mg/kg q8h for maintenance. 6) Levetiracetam: 20-60 mg/kg IV or PO q8h. 7) Activated charcoal: 1-2 g/kg PO, with a cathartic (e.g., sorbitol 70% at 3 mL/kg) or magnesium sulfate (250 mg/kg PO). 8) Apomorphine: 0.03 mg/kg IV or 0.04 mg/kg IM; or 0.25 mg in the conjunctival sac. 9) Hydrogen peroxide: 1-2 mL/kg PO, up to 50 mL, can be repeated once after 15 minutes if no emesis. 10) Sodium bicarbonate: 0.5-1 mEq/kg IV slowly, only if pH < 7.1. 11) Fluid therapy: Lactated Ringer's solution or 0.9% NaCl at 60-100 mL/kg/day for maintenance, plus deficits; adjust based on hydration status and ongoing losses. 12) Potassium chloride: add to fluids at 20-40 mEq/L, not to exceed 0.5 mEq/kg/hour. 13) For hyperthermia: cool with cool water and fans; avoid ice baths. 14) For aspiration pneumonia: amoxicillin-clavulanate (12.5-25 mg/kg PO q8h) or enrofloxacin (5-10 mg/kg PO q24h) if indicated. 15) For acute kidney injury: manage with fluid therapy and consider furosemide (1-2 mg/kg IV q8h) if oliguric. All dosages should be adjusted based on the animal's condition and response to therapy.

Evidence-based literature on metaldehyde toxicosis is limited, but several studies and reviews provide guidance. A retrospective study by Richardson et al. (2003) reported on 100 cases of metaldehyde poisoning in dogs, finding that the most common clinical signs were tremors, seizures, and hyperthermia, and that treatment with decontamination, anticonvulsants, and supportive care resulted in a survival rate of 97%. Another study by Bates et al. (2012) evaluated the efficacy of methocarbamol in controlling tremors in dogs with metaldehyde toxicosis, showing that it was effective in reducing tremor severity without significant adverse effects. A review by Talcott (2013) in Veterinary Toxicology emphasized the importance of early decontamination and aggressive seizure management. The ACVIM consensus statement on the management of seizures in dogs (2016) provides guidelines for anticonvulsant therapy that are applicable to toxicant-induced seizures. Additionally, the ASPCA Animal Poison Control Center has published data on metaldehyde toxicosis, reporting that the median lethal dose in dogs is 100-200 mg/kg and that clinical signs can be managed with supportive care. Overall, the literature supports a favorable prognosis with prompt and aggressive treatment, and emphasizes the need for owner education on the dangers of metaldehyde-containing products.